Release: June 11,2021

Expiration: June 11, 2021

Click "Disclaimer" for additional CME information.

---

This activity is jointly provided by Global Education Group and Avlis International, Inc.

This activity is supported by an educational grant from Genentech.

Target Audience

The educational design of this activity addresses the needs of Retina Specialists, Retina Fellows, Ophthalmologists (general/comprehensive), Optometrists, and allied health professionals involved in the treatment of patients with nAMD.

Statement of Need/Program Overview

Therapeutic options for prevention and management of diabetic eye disease have expanded, as recent trial data (PANORAMA; DRCR Protocol W) have established that therapeutic intervention can reverse disease progression (improvements in Diabetic Retinopathy Severity Scale) in diabetic patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). This treatment of NPDR may go beyond the current treatment algorithm and provide an opportunity to prevent progression to neovascular vision-threatening complications or DME, thereby lowering burden of illness, and enhancing visual outcomes and overall quality of life for patients. Additionally, physicians are faced with new challenges associated with patient care and adherence in the era of COVID-19.

Activities Included:

Pre-Questions

Podcast with Dr. Arshad Khanani and Dr. Nancy Holecamp

Podcast with Dr. Arshad Khanani and Dr. Carl Regillo

Podcast with Dr. Arshad Khanani and Dr. Michael Singer

Post-Questions

Evaluation